GlassScriptPhysician profile
Alan J Briker
NPI 1942238654
$4,283.40
in general payments reported to CMS, 2019-2025
44 companies · $1,018 in 2025
The $1,018 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $561 · 2020: $57.14 · 2021: $129 · 2022: $1,113 · 2023: $600 · 2024: $805 · 2025: $1,018.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,377 · Education: $46.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,376.63 |
| Education | $46.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $635.35 | 2019-2025 | Tremfya, Stelara, Simponi |
| Corcept Therapeutics | $441.04 | 2024-2025 | Korlym |
| Novo Nordisk INC | $351.50 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Takeda Pharmaceuticals U.S.A., INC. | $351.04 | 2019-2025 | Entyvio, Eohilia |
| Biohaven Pharmaceutical Holding Company LTD. | $309.80 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $256.00 | 2019-2023 | Xifaxan, Trulance |
| Qol Medical, LLC | $255.23 | 2022-2025 | Sucraid, Sucraid |
| Medtronic, INC. | $222.26 | 2022-2023 | Appose Ulc |
| Glaxosmithkline, LLC. | $145.14 | 2022-2025 | Shingrix, Arexvy |
| Asensus Surgical, INC. | $119.71 | 2022-2023 | Senhance |
| Lilly USA, LLC | $111.19 | 2022-2024 | Mounjaro, Omvoh |
| Xeris Pharmaceuticals, INC. | $101.00 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Regeneron Healthcare Solutions, INC. | $98.59 | 2023-2025 | Dupixent |
| Amgen INC. | $90.19 | 2022-2025 | Evenity, Prolia |
| Ardelyx, INC. | $86.12 | 2022-2024 | Ibsrela |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $63.50 | 2024 | Breztri |
| Abbvie INC. | $52.27 | 2019-2020 | |
| Daiichi Sankyo INC. | $48.62 | 2025 | Injectafer |
| Phathom Pharmaceuticals, INC. | $37.50 | 2025 | Voquezna |
| Merck Sharp & Dohme LLC | $34.02 | 2024 | Zinplava, Dificid |
| Madrigal Pharmaceuticals | $33.81 | 2025 | Rezdiffra |
| Tandem Diabetes Care, INC. | $31.90 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Intercept Pharmaceuticals, INC. | $28.99 | 2019-2023 | Ocaliva |
| Pfizer INC. | $28.98 | 2023-2025 | |
| Ferring Pharmaceuticals INC. | $28.67 | 2019-2022 | |
| Ibsa Pharma INC. | $23.59 | 2025 | Flector, Tirosint, Licart |
| Ironwood Pharmaceuticals, INC | $23.18 | 2019 | |
| Dexcom, INC. | $20.91 | 2023 | Dexcom G6 Transmitter |
| Kyowa Kirin, INC. | $19.98 | 2025 | |
| Blueprint Medicines Corporation | $19.51 | 2024 | Ayvakit |
| Boston Scientific Corporation | $19.09 | 2019 | |
| Depuy Synthes Sales INC. | $17.64 | 2019 | |
| Astellas Pharma US INC | $17.29 | 2025 | Veozah |
| Sandoz INC. | $17.16 | 2023 | Hyrimoz |
| Celgene Corporation | $16.67 | 2023 | Reblozyl |
| Echosens North America, INC. | $15.30 | 2024 | Fibroscan |
| Fresenius Kabi USA, LLC | $15.00 | 2023 | |
| Gilead Sciences, INC. | $14.74 | 2019 | |
| Sanofi Pasteur INC. | $14.62 | 2023 | |
| Dynavax Technologies Corporation | $14.28 | 2023 | Heplisav-B |
| Braintree Laboratories, INC. | $13.81 | 2024 | Sutab, Suflave |
| Amarin Pharma, INC. | $13.76 | 2019 | |
| Dova Pharmaceuticals | $13.65 | 2019 | |
| Allergan, INC. | $10.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Briker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.